Business
Collaboration with University Clinic Dresden
Collaboration with University Clinic Dresden.
About this update from Genincode Plc
[{"type":"text","content":"\n\nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nCollaboration with University Clinic Dresden for implementation of LIPID inCode®\nLIPID inCode® becomes first polygenic test for CVD implemented in Germany\n \nOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with the University Clinic Dresden, Department of Internal Medicine and Department of Human Genetics, based in Germany, to use its LIPID inCode® test in primary care for the diagnosis of hypercholesterolemia (high levels of cholesterol) and familial hypercholesterolemia (\"FH\"). LIPID inCode® is the first polygenic product to be introduced in Germany to improve the diagnosis and treatment of hypercholesterolemia to prevent cardiovascular disease (\"CVD\"). This new endeavour is based on a long-standing clinical research collaboration of GENinCode with the Department of Medicine (Prof. Dr. S. Bornstein).\n \nThe University Clinic lipid centre treats over 6000 patients with lipid disorders and constitutes the largest academic lipid apheresis centre globally. In Germany, 60% of the population suffer from high levels of cholesterol and it is estimated that over a quarter of a million of these cases relate to FH1. The collaboration also builds on the Transcampus Initiative between Technische Universität in Dresden and Kings College London, providing a translational model of best practice and patient care across borders.\n \nLIPID inCode® testing will initially support the lipid centre in the region of Saxony to deliver its preventative care plans to identify individuals at risk of CVD. The lipid centre, will handle the regional roll-out of testing and may extend testing to other regions of Germany. LIPID inCode® improves the diagnosis and treatment of familial hypercholesterolemia with rapid turnaround of test results to prevent the onset of CVD. It is also the first commercially available polygenic test for CVD to be implemented in Germany. \n \nThe collaboration follows the positive results of the LIPID inCode® Dresden clinical study and pilot. LIPID inCode® testing in the Saxony region will cover a primary care population and community practice in the region. Testing will diagnose patients with genetic disorders giving rise to high ...